Galantamine for Alzheimer's Disease: Cochrane Review
Cochrane Database of Systematic Reviews (2006)
Significant cognitive and global function improvement vs placebo across multiple RCTs with acceptable tolerability.
Galantamine
Oral tablet (8mg)Available in all 50 statesMarketing purposes only. Actual medications, if prescribed, are dispensed by a licensed pharmacy.
sleep
GalantamineGalantamine
Dual-mechanism cholinesterase inhibitor and allosteric nicotinic receptor modulator. FDA-approved for Alzheimer's dementia. Used off-label for cognitive enhancement, lucid dreaming, and smoking cessation support.
Dual mechanism: AChE inhibition + nicotinic modulation
Cognitive improvement in Alzheimer's
May enhance nicotinic receptor function
Promotes lucid dreaming
No commitment · HSA/FSA eligibleNo commitment · HSA/FSA eligible
How it works
Mechanism of action
Competitively inhibits acetylcholinesterase, increasing synaptic acetylcholine. Additionally acts as positive allosteric modulator at nicotinic acetylcholine receptors (α4β2 and α7), enhancing cholinergic neurotransmission beyond simple enzyme inhibition.
The baseline panel.
Every Marek client receives this baseline panel before a provider review. Your provider may add additional biomarkers based on your health history, symptoms, and goals, pulling from 1,000+ available markers. See more biomarkers →
Hormone Profile
12 markers
Sex hormones
- Total TestosteroneLC/MS
- Free TestosteroneEquilibrium Dialysis
- Estradiol, Sensitive / UltrasensitiveLC/MS
- Sex Hormone Binding Globulin (SHBG)
- ProgesteroneLC/MSFemale panel
- Prolactin
- Luteinizing Hormone (LH)
- Follicle-Stimulating Hormone (FSH)
- hCG, Total, QuantitativeFemale panel, pre-menopause
Adrenals & neurosteroids
- Cortisol
- DHEA-S
Growth hormone / IGF-1
- Insulin-Like Growth Factor I (IGF-1)
Thyroid Status
3 markers
Thyroid hormones
- Thyroid Stimulating Hormone (TSH)
- Free T4
- Free T3
Heart Health
9 markers
Cardiovascular health
- Total Cholesterol
- HDL Cholesterol
- LDL Cholesterol
- LDL:HDL Ratio
- VLDL Cholesterol
- Triglycerides
- Apolipoprotein-B (ApoB)
- C-Reactive Protein, High Sensitivity (hsCRP)
- Lipoprotein(a) (Lp(a))
Metabolism
3 markers
Insulin sensitivity
- Blood Glucose
- Fasting Insulin
- HbA1c
Organ Function
26 markers
Liver & pancreas
- AST
- ALT
- Bilirubin, Total
- γ-Glutamyl Transferase (GGT)
Kidney function
- BUN
- Creatinine w/ eGFR
Comprehensive Metabolic Panel (CMP)
- Glucose
- Blood Urea Nitrogen (BUN)
- Creatinine
- eGFR
- BUN/Creatinine Ratio
- Sodium
- Potassium
- Chloride
- Carbon Dioxide, Total
- Calcium
- Protein, Total
- Albumin
- Globulin, Total
- Albumin/Globulin (A/G) Ratio
- Alkaline Phosphatase (ALP)
- AST
- ALT
Prostate health
- Prostate-Specific Antigen (PSA)Male panel
- Free PSAMale panel
- % Free PSAMale panel
Nutrient Status
31 markers
Vitamins & minerals
- Vitamin D, 25-OHD (25-Hydroxy)
- Magnesium, RBC
Iron status
- Iron
- Iron Saturation
- TIBC
- UIBC
- Ferritin
Complete Blood Count (CBC)
- White Blood Count (WBC)
- Red Blood Count (RBC)
- Hemoglobin (Hgb)
- Hematocrit (HCT)
- MCV
- MCH
- MCHC
- Red Cell Distribution Width (RDW)
- Platelets
- Neutrophils
- Neutrophils (Absolute)
- Lymphocytes
- Lymphocytes (Absolute)
- Neutrophil/Lymphocyte Ratio
- Monocytes
- Monocytes (Absolute)
- Eosinophils
- Eosinophils (Absolute)
- Basophils
- Basophils (Absolute)
- Immature Cells
- Immature Granulocytes
- Immature Granulocytes (Absolute)
- NRBC, w/ Reflex for Immature Cells
Clinical evidence
The research behind Galantamine.
Safety profile
Monitoring & safety information.
Commonly reported side effects
- Nausea
- Vomiting
- Diarrhea
- Dizziness
- Decreased appetite
- Vivid dreams
Less common but serious risks
- Bradycardia (cholinergic effect)
- GI bleeding (especially with NSAIDs)
- Syncope
Generally not appropriate for
- Severe hepatic/renal impairment
- GI obstruction
- Urinary obstruction
Typical monitoring
- Heart rate
- GI symptoms
- Cognitive assessments
- Weight
FAQ
Quick answers.
Dual-mechanism cholinesterase inhibitor and allosteric nicotinic receptor modulator. FDA-approved for Alzheimer's dementia. Used off-label for cognitive enhancement, lucid dreaming, and smoking cessation support.
Dual mechanism: AChE inhibition + nicotinic modulation. Cognitive improvement in Alzheimer's. May enhance nicotinic receptor function. Promotes lucid dreaming.
Common side effects include: nausea, vomiting, diarrhea, dizziness, decreased appetite, vivid dreams. Most side effects are dose-dependent and may resolve with continued use or dose adjustment.
Dual-mechanism cholinesterase inhibitor and allosteric nicotinic receptor modulator. FDA-approved for Alzheimer's dementia. Used off-label for cognitive enhancement, lucid dreaming, and smoking cessation support.
Treatments are dependent on licensed clinical prescription. Client costs vary based on individual labs and panel in treatments and services.